LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

ABBV

193.29

-1.3%↓

Inicio・Lista de Acciones・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Cerrado

Sector Salud

1.37 -1.44

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.36

Máximo

1.4

Métricas clave
By Trading Economics
Ingresos	15M 614K
Ventas	14M 56M
P/B Media del Sector	26.504 102.974
BPA	-0.08
Margen de beneficio	1.093
Empleados	167
EBITDA	14M 11M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+346.43 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	10M 322M
Apertura anterior	2.81
Cierre anterior	1.37

Noticias sobre sentimiento de mercado

By Acuity

100%

337 / 366 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

1.35 / 1.42 Soporte y Resistencia

Akebia Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

28 mar 2024, 10:30 UTC

Principales Movimientos del Mercado

Akebia Shares Rally Premarket After FDA Approves Vafseo

Comparación entre iguales

Cambio de precio

Akebia Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

346.43% repunte

Estimación a 12 meses

Media 6.25 USD 346.43%

Máximo 7.5 USD

Mínimo 5 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Akebia Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Akebia Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.35 / 1.42Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

337 / 366 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Akebia Therapeutics Inc

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.